International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 4 , Pages 1218-1221 , 15 November 2007

Improving the Capture of Adverse Event Data in Clinical Trials: The Role of the International Atomic Energy Agency

  • Susan E. Davidson, M.D.

      Affiliations

    • Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
    • Corresponding Author InformationReprint requests to: Susan E. Davidson, M.D., Department of Clinical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom. Tel: (+44) 161-446-3410; Fax: (+44) 161-44-8014
    • ,
  • Andy Trotti, M.D.

      Affiliations

    • Division of Radiation Oncology, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL
    • ,
  • Özlem U. Ataman, M.D., Ph.D.

      Affiliations

    • Dokuz Eylul University Oncology Institute, Izmir, Turkey
    • ,
  • Jinsil Seong, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University Medical College, Seoul, South Korea
    • ,
  • Fen Nee Lau, M.D.

      Affiliations

    • Institute of Radiotherapy and Oncology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
    • ,
  • Neiro W. da Motta, M.D., Ph.D.

      Affiliations

    • Fundaçao Faculdade Federal de Ciencias Medicas de Porto Alegre, Servico de Radioterapia, Porto Alegre, Brazil
    • ,
  • Branislav Jeremic, M.D., Ph.D.

      Affiliations

    • International Atomic Energy Agency, Vienna, Austria

Received 13 February 2007 ,Revised 25 April 2007 ,Accepted 29 April 2007.

References 

  1. Chen Y, Trotti A, Coleman CN, et al. Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation. Int J Radiat Oncol Biol Phys. 2006;64:1442–1451
  2. Bentzen SM. Towards evidence based radiation oncology: Improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother Oncol. 1998;46:5–18
  3. National Cancer Institute. CTC v2.0 and common terminology criteria for adverse events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed May 6, 2007.
  4. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69–76
  5. Gwede CK, Johnson DJ, Daniels SS, et al. Assessment of toxicity in cooperative oncology clinical trials: The long and short of it. J Oncol Manag. 2002;11:15–21
  6. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol. 2006;24:3933–3938
  7. Denton AS, Bond SJ, Matthews S, et al. National audit of the management and outcome of carcinoma of the cervix treated with radiotherapy in 1993. Clin Oncol (R Coll Radiol). 2000;12:347–353
  8. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol. 2006;7:903–909
  9. Livsey JE, Routledge J, Burns M, et al. Scoring of treatment-related late effects in prostate cancer. Radiother Oncol. 2002;65:109–121
  10. Olopade FA, Norman A, Blake P, et al. A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy. Br J Cancer. 2005;92:1663–1670
  11. Jensen K, Bonde Jensen A, Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. Radiother Oncol. 2006;78:298–305
  12. Stephens RJ, Hopwood P, Girling DJ, et al. Randomized trials with quality of life endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?. Qual Life Res. 1997;6:225–236
  13. Baumann M, Bentzen SM. Clinical manifestations of normal-tissue damage. In:  Steel GG editors. Basic clinical radiobiology. London: Arnold; 2002;p. 105–119
  14. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22:3485–3490
  15. Davidson SE, Burns M, Routledge J, et al. Short report: A morbidity scoring system for Clinical Oncology practice: Questionnaires produced from the LENT SOMA scoring system. Clin Oncol (R Coll Radiol). 2002;14:68–69
  16. Routledge JA, Burns MP, Swindell R, et al. Evaluation of the LENT-SOMA scales for the prospective assessment of treatment morbidity in cervical carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:502–510
  17. Davidson SE, Burns MP, Routledge JA, et al. Assessment of morbidity in carcinoma of the cervix: A comparison of the LENT SOMA scales and the Franco-Italian glossary. Radiother Oncol. 2003;69:195–200
  18. Chassagne D, Sismondi P, Horiot JC, et al. A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol. 1993;26:195–202
  19. Drummond HE, Ghosh S, Ferguson A, et al. Electronic quality of life questionnaires: A comparison of pen-based electronic questionnaires with conventional paper in a gastrointestinal study. Qual Life Res. 1995;4:21–26
  20. Velikova G, Wright EP, Smith AB, et al. Automated collection of quality-of-life data: A comparison of paper and computer touch-screen questionnaires. J Clin Oncol. 1999;17:998–1007
  21. Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol. 2005;23:3552–3561
  22. Ataman OU, Barrett A, Filleron T, et al. Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: A study of the REACT working group of ESTRO. Radiother Oncol. 2006;78:95–100
  23. Cull A, Sprangers M, Bjordal K, et al. EORTC quality of life study group translation procedure. In. Brussels; 1998. pp. 1–31. Available at: www/eortc.be/home/gol/manuals. Accessed May 6, 2007.
  24. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181

 The International Atomic Energy Agency (IAEA) Consultant's meeting was held October 15, 2005, Denver, CO. The IAEA provided financial support for this meeting.

 Conflict of interest: none.

PII: S0360-3016(07)00808-5

doi: 10.1016/j.ijrobp.2007.04.054

International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 4 , Pages 1218-1221 , 15 November 2007

Article Tools